Maria Grunwald
Keine laufenden Positionen mehr
Profil
Dr. Maria Grunwald is a Director-Business Development at Office of Technology Development.
She joined OTD in 2012.
Dr. Grunwald was previously employed as a Consultant by Dyax Corp.
Dr. Grunwald received her MBA from the Massachusetts Institute of Technology and a doctorate degree from Johns Hopkins University.
Ehemalige bekannte Positionen von Maria Grunwald
| Unternehmen | Position | Ende |
|---|---|---|
| DYAX CORP. | Corporate Officer/Principal | - |
| RADIUS HEALTH, INC. | Berater | - |
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Vertrieb & Marketing | - |
Ausbildung von Maria Grunwald
| The Johns Hopkins University | Doctorate Degree |
| Massachusetts Institute of Technology | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
